CAR T-Cell Therapy Expands to Autoimmune Diseases: Preliminary Data Reported from ~300 CD19-Targeted Treatments

July 5, 2026

RheumNow.com USA

Overview

CAR T-cell therapy is now being actively investigated not only for specific blood cancers but also as a treatment for autoimmune diseases such as systemic lupus erythematosus (SLE). As of May 2026, preliminary data from approximately 300 patients worldwide treated with CD19-targeted CAR T-cell therapy have been released, demonstrating promising efficacy and a manageable safety profile. Currently, 18 Phase 2 or Phase 3 clinical trials are underway, rigorously evaluating efficacy, durability of response, immune reconstitution, and safety. This novel application holds the potential to dramatically transform treatment options for refractory autoimmune diseases and marks a significant expansion of CAR T-cell therapy beyond oncology.

In Depth

Key Findings

Following its success in treating specific hematological malignancies, CAR T-cell therapy is rapidly gaining attention as a promising therapeutic approach for severe autoimmune diseases such as systemic lupus erythematosus (SLE). As of May 2026, preliminary data from approximately 300 patients worldwide, treated with CD19-targeted CAR T-cell therapy, have been published, indicating favorable efficacy and a manageable safety profile.

Technical / Clinical Details

CAR T-cell therapy in autoimmune diseases is often designed to target the CD19 antigen expressed on B cells. Since B cells play a central role in producing autoantibodies and regulating immune responses, their depletion is believed to lead to an improvement in the pathophysiology of autoimmune diseases. The process involves collecting a patient’s own T-cells, genetically modifying and expanding them ex vivo to express the CAR, and then reinfusing them back into the patient, similar to cancer treatment. Preliminary clinical trial data show that in SLE patients, CAR T-cell therapy can induce rapid and deep disease remission, with the potential to significantly reduce the need for steroids and other immunosuppressive agents. The primary side effects observed were similar to cytokine release syndrome (CRS) and neurotoxicity (ICANS) reported in cancer treatments, but generally trended towards lower severity in autoimmune disease patients. Currently, 18 Phase 2 or Phase 3 clinical trials are underway, meticulously evaluating improvements in disease activity, duration of remission, patterns of immune reconstitution post-treatment, and long-term safety profiles.

Background & Context

Autoimmune diseases arise when the immune system mistakenly attacks its own tissues, leading to chronic inflammation, organ damage, and diminished quality of life. Existing treatments have limitations, with many patients failing to respond or suffering from severe side effects. The success of CAR T-cell therapy in cancer, owing to its powerful cell-depleting capabilities and persistence, has generated the hypothesis that it could be applied to autoimmune diseases. Particularly in conditions like SLE, where B cells are deeply implicated in pathogenesis, their eradication could address the underlying cause of the disease. This application represents a significant advancement, showcasing the versatility of CAR T-cell technology and its potential for broad application beyond oncology.

Strategic Significance & Outlook

The future outlook for CAR T-cell therapy in autoimmune diseases is exceptionally bright. The results from ongoing late-stage clinical trials will provide crucial information that determines its establishment as a standard therapy. Key evaluation points will include the duration of remission and the risk of reappearance of autoreactive B cells after immune reconstitution. Furthermore, reducing the manufacturing cost of CAR T-cell therapy and developing allogeneic (off-the-shelf) CAR T-cell platforms are indispensable for expanding access to a greater number of autoimmune disease patients. This technology holds potential for application in various B cell-mediated autoimmune diseases beyond SLE, such as systemic sclerosis, multiple sclerosis, and myasthenia gravis, opening new frontiers in immunology and cell therapy.

Source: https://rheumnow.com/therapeutic-update/fundamentals-car-t-cell-therapy-and-its-investigational-use-autoimmune-diseases

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.